| Literature DB >> 30062135 |
Maria J Duarte1,2, Elliott D Kozin1,2, Miriam B Barshak2,3,4, Katherine Reinshagen2,5, Renata M Knoll2, Kalil G Abdullah6, D Bradley Welling1,2, David H Jung1,2.
Abstract
OBJECTIVE: Otogenic brain abscesses are one of the most significant life-threatening complications of otologic infections. Given their low prevalence, otogenic brain abscesses require a high index of suspicion for diagnosis. In this systematic review, we aim to provide an analysis of otogenic brain abscesses and describe common clinical signs and symptoms, bacteriology, location, treatment options, morbidity, and mortality. DATA SOURCES: PubMed, Cochrane CENTRAL database, Google Scholar, and Scopus.Entities:
Keywords: Brain abscess; computed tomography; magnetic resonance imaging; otologic infection
Year: 2018 PMID: 30062135 PMCID: PMC6057212 DOI: 10.1002/lio2.150
Source DB: PubMed Journal: Laryngoscope Investig Otolaryngol ISSN: 2378-8038
Figure 1Coronal T1 fat‐suppressed post gadolinium (A) and axial T2 (B) MR images demonstrate an intra‐axial left temporal lobe peripherally enhancing lesion (white asterisk), adjacent dural enhancement (white arrowhead) and a peripheral rim of T2 hypointense signal (short white arrow). There is surrounding edema resulting in uncal herniation (long white arrow). On coronal (C) and axial (D) CT, there is a soft tissue mass in the left middle ear and mastoid with erosion of the middle ear ossicles (black arrowhead), expansion of the aditus ad antrum (black asterisk) and erosion of the tegmen (black arrow).
Fourteen‐Item Checklist to Assess Methodological Quality of Studies.
|
1. Clear description of research design, eg, observational, prospective, or retrospective |
Figure 2Flowchart demonstrating the study selection process, following the established Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) recommended guidelines.
Studies Meeting Inclusion and Exclusion Criteria.
| Publication | Date Range | Design, Evidence Level, Quality | n (abscesses) | n (otogenic abscesses) | Age | Gender |
|---|---|---|---|---|---|---|
| Yang, 1981 | 1952–1972 | RCR, III, mod | 400 | 263 | 85% under 65 y | 71% M |
| Bradley et al., 1984 | 1950–1979 | RCR, III, high | 139 | 139 | 4.5–76 y | 2.5:1 M:F |
| Keet et al., 1990 | 1952–1986 | RCR, III, mod | 641 | 233 | Not specified | Not specified |
| Samuel et al., 1986 | 1978–1983 | RCR, III, mod | 53 | 53 | 75% under age 15 y | 59% M |
| Nahoo et al., 2011 | 1983–2002 | RCR, III, high | 973 | otorhinogenic: 369 | Not specified | 74.2% M, (for all abscesses) |
| Rupa and Raman,1991 | 1981–1989 | RCR, III, mod | 27 | 27 | 83.6% under 25 y | 2:1 M to F |
| Beller et al., 1973 | 1941–1971 | RCR, III, high | 89 | 27 | 2 mo–70 y; 43% under 15 y | 60 M |
| Sichiza et al., 2005 | 1993–2003 | RCR, III, high | 121 | 25 | Not specified | 101 M |
| Carey et al., 1972 | 1946–1965 | RCR, III, mod | 86 | Sinus or mastoid: 25 | Not specified | Not specified |
| Kangsanarak et al, 1995 | 1978–1990 | RCR, III, high | 29 | 29 | 60% of otogenic abscess patients were between 11–20 y | Not specified |
| Lakshmi et al. 1993 | 1987–1991 | RCR, III, mod | 50 | 25 | 1–55 y | 41 M |
| Pennybacker et al., 1961 | 1960 | RCR, III, high | 85 | 85 | Not specified | Not specified |
| Dawes et al., 1960 | 1944–1960 | RCR, III, mod | 30 | 30 | 0–80; greatest amount 10–20 y | Not specified |
| Morgan et al., 1973 | 1946–1971 | RCR, III, high | 88 | 21 | 2 mo–69 y; most between 10–20 y | 61 M |
| Lavin et al., 2016 | 2009 | RCR, III, low | 37 | 37 | Not specified | Not specified |
| Penido et al., 2005 | 1987–2002 | RCR, III, high | 26 | 26 | 6 mo–79 y; 66% of patients younger than 25 y | |
| Prasad et al., 2006 | 1997–2004 | Prospective cultures/RCR, III, high | 118 | 37 | 3 mo–63 y (for all abscesses) | 95 M (for all abscesses) |
| Nunez and Browning, 1990 | 1976–1986 | RCR, III, mod | 517 | 44 | 0–80; equally distributed | 31 M |
| Newlands, 1965 | 1953–1962 | RCR, III, high | 80 | 80 | 7–80 y | 63 M |
| Sennaroglu and Sozeri, 2000 | 1968–1999 | RCR, III, high | 41 | 41 | 65% between 5–15 | 27 M |
| Brand et al., 1984 | 1962–1982 | RCR, III, high | 17 | 15 | 8–65y | 12 M |
| Osma et al., 2000 | 1990–1999 | RCR, III, high | 10 | 10 | 7–49 y, 58% under age 20 | 67% M |
| Yen et al., 1995 | 1981–1994 | RCR, III, high | 93 | 19 | 1 mo–79 y (for all abscesses) | 3.1:1 M to F |
| Chun et al., 1986 | 1970–1983 | RCR, III, high | 45 | 7 | 5–79 y (for all abscesses) | 33 M (for all abscesses) |
| Carpenter and Holliman, 2007 | 2000–2004 | RCR, III, high | 49 | 4 | 8–77 (for all abscesses) | 1.7:1 M to F (for all abscesses) |
| Kao et al., 2003 | 1991–2001 | RCR, III, high | 53 | 8 | 19–70 y | 5 M |
| Barry et al., 1999 | 1977–1995 | RCR, III, high | 4 | 3 | Not specified | Not specified |
| Murthy et al., 1991 | 1984–1990 | RCR, III, high | 10 | 10 | 6–15 y | 2 M |
| Sun and Sun, 2013 | 1996–2012 | RCR, III, high | 9 | 9 | For all patients with complicated OM: 12–62 y | For all patients with complicated OM: 12 M 5 F |
Most studies focused on brain abscesses over a certain time period, of which a subset were otogenic in origin. There were some that focused on only otogenic abscesses and some that focused on complications of ear disease. All study designs were Retrospective Cohort Studies (RCR). Corresponding levels of evidence are based on the Centre for Evidence‐Based Medicine, Oxford, where III‐IV represents cohort studies. A level of evidence of IV is assigned to poor quality cohort studies, based on available data and design. The quality of evidence is based on a 14‐item checklist was generated a priori, taking into account research design, patient selection, and presentation of outcome data (Table 1). Criteria were chosen based on previous systematic reviews. Studies were assigned one point based on each listed criteria. Studies with a total score of 10 to 14 points were considered “high quality”; studies with a score of 6 to 9 were considered “moderate quality”; and studies with a score of 0 to 5 were considered “low quality.” M, Male; F, Female; y, years.
Figure 3Location of otogenic intracranial abscesses across all studies. The location of 905 out of 1302 total otogenic abscesses was specified. Most were located in the temporal lobe (n = 722, 55% of total) or cerebellum (n = 369, 28% of total). “Other” includes frontal lobe, parietal lobe and subdural locations (n = 66, 5% of total). The location of 145 otogenic abscesses was not specified (11%).
Location of Otogenic Abscesses.
| Publication | n (otogenic) | Temporal lobe n (%) | Cerebellar lobe n (%) | Other n (%) |
|---|---|---|---|---|
| Yang, 1981 | 263 | 168 (42%) | 112 (28%) | 50 (12.5%) |
| Keet et al., 1990 | 233 | 140 (60%) | 70 (30%) | |
| Bradley et al., 1984 | 139 | 76 (54%) | 39 (25%) | |
| Pennybacker et al., 1961 | 85 | 55 (65%) | 30 (35%) | |
| Newlands, 1965 | 80 | 52 (65%) | 25 (31%) | 3 (3.75%) |
| Fernandes et al., 1986 | 53 | Not specified | 10 (18%) | |
| Sennaroglu and Sozeri, 2000 | 41 | 44 (22%) | 8 (18%) | |
| Nunez and Browning, 1990 | 41 | 29 (70%) | 19 (46%) | |
| Prasad et al., 2006 | 37 | Not specified | Not specified | |
| Lavin et al., 2016 | 37 | Not specified | Not specified | |
| Dawes et al., 1960 | 30 | Not specified | Not specified | |
| Kangsanarak et al., 1995 | 29 | 20 (84%) | 9 (31%) | |
| Sichiza et al., 2005 | 27 | 23 (84%) | 4 (16%) | |
| Rupa and Raman,1991 | 27 | 12 (44%) | 15 (55%) | |
| Beller et al., 1973 | 27 | 14 (52%) | 4 (16%) | |
| Penido et al., 2005 | 26 | Not specified | Not specified | |
| Lakshmi et al., 1993 | 24 | 6 (24%) | 4 (16%) | 12 (49%) |
| Morgan et al., 1973 | 21 | 19 (90%) | Not specified | |
| Yen et al., 1995 | 19 | 31 (11%) | 1 (6%) | |
| Brand et al., 1984 | 15 | 10 (66%) | Not specified | |
| Osma et al., 2000 | 10 | 9 (90%) | 1 (10%) | |
| Murthy et al., 1991 | 10 | 2 (20%) | 8 (80%) | |
| Sun and Sun, 2013 | 9 | 5 (55%) | 5 (44%) | |
| Kao et al., 2003 | 8 | 4 (50%) | 1 (12.5%) | 1 (12.5%) |
| Chun et al., 1986 | 7 | 3 (43%) | 4 (57%) | |
| Carpenter and Holliman, 2007 | 4 | Not specified | Not specified | |
| Barry et al., 1999 | 3 | Not specified | Not specified | |
| Total otogenic: 1302 | Total Temporal lobe: 722 (55%) | Total Cerebellar: 369 (28.3%) | Total Other: 66 (5%) |
Figure 4Complications: 12 of 18 studies specified complications in patients with otogenic abscesses. Out of the 681 otogenic abscesses covered in those studies, 238 (35%) were cases with complications. The figure demonstrates the most common complications patients suffered.
Figure 5Microbiology. Microbiology data was available from 14 studies that specified a total of 16 common isolates from otogenic intracranial abscesses. Eleven of 14 (78.5%) of studies had P. mirabilis as the most common isolate while 1 of 14 (7.1%) specified Streptococcus species as the most common isolate. Two studies had more than one common isolate: one with P. mirabilis + Streptococcus species and one with Streptococcus and Staphylococcus species.
Microbiological Isolates in Intracranial Otogenic Abscesses Across All Studies.
| Publication | Primary isolate |
|---|---|
| Yang, 1981 |
|
| Newlands, 1965 |
|
| Sennaroglu and Sozeri, 2000 |
|
| Kangsanarak et al., 1995 |
|
| Rupa and Raman,1991 |
|
| Sichiza et al., 2005 |
|
| Morgan et al., 1973 | Streptococci and Staphylococi |
| Yen et al., 1995 |
|
| Sun and Sun, 2013 |
|
| Kao et al., 2003 |
|
| Nahoo et al., 2011 |
|
| Dawes et al., 1960 |
|
| Penido et al., 2005 |
|
| Barry et al., 1999 |
|
Complications and Mortality from Brain Abscesses Across All Studies
| Publication | Complications | Mortality | Other Complications |
|---|---|---|---|
| Yang, 1981 | Herniation in 25.8% of cases | 21% | None specified |
| Keet et al., 1990 | Not specified | 37% | None specified |
| Bradley et al., 1984 | 44% of patients undergoing radical mastoidectomy required further aural surgery after abscess decompressed due to persistent disease | 47.2% | Epilepsy (23%), ataxia (13.8%), hemiplegia (12%), visual disturbance (7%), dysphagia (7.7%) |
| Pennybacker et al., 1961 | 23% | Not specified | |
| Newlands, 1965 | 10% with concurrent meningitis | 275% | Not specified |
| Samuel et al., 1986 | Not specified | 36% | None specified |
| Nunez and Browning, 1990 | Not specified | 20% | Not specified |
| Sennaroglu and Sozeri, 2000 | 32% with concurrent meningitis | 29% overall; 45% before CT and 10% after CT | 31%of cases required revision surgery |
| Lavin et al., 2016 | Not specified | Not specified | Not specified |
| Prasad et al., 2006 | Not specified | Not specified | Not specified |
| Dawes et al., 1960 | 73% of abscesses with multiple foci | 50% | Not specified |
| Kangsanarak et al., 1995 | Not specified | 31% | Not specified |
| Rupaand Raman,1991 | Not specified | Not specified | None specified |
| Beller et al., 1973 | Not specified | 40% | Epilepsy (15%), Permanent neurologial deficit (33%), |
| Sichiza et al., 2005 | Not specified | 13% | Epilepsy (11%), hemiparesis (5%) |
| Penido et al., 2005 | 55% of cases developed more than one intracranial complication | Not specified | Not specified |
| Lakshmi et al., 1993 | Notspecified | Not specified | Not specified |
| Morgan et al., 1973 | Not specified | 36.4% | Seizures (48%), Severe neurological deficit (17%) |
| Yen et al., 1995 | Not specified | 5% | 5% permanent deficit |
| Brand et al., 1984 | Not specified | 26.6% (all before CT scan) | 6.6% incomplete aphasia, 6.6% facial nerve paralysis; 6.6% other permanent neurological deficit |
| Osma et al., 2000 | Not specified | 20% | Not specified |
| Murthy et al., 1991 | 30% with mastoiditis | 0% | 0 |
| Sun and Sun, 2013 | Not specified | 0% | 0 |
| Kao et al., 2003 | Not specified | 12.5% | |
| Chun et al., 1986 | Not specified | Not specified | Not specified |
| Carpenter and Holliman, 2007 | Not specified | 0% | 0 |
| Barry et al., 1999 | 100% concurrent meningitis | Not specified | Not specified |
| Nahoo et al., 2011 | Otic hydrocephalus developed in 6 patients and 13 patients required repeat surgery. | 29.4% | None specified |
| Carey et al., 1972 | Excessive bleeding (30%) | 53% | Epilepsy (26%) |
Figure 6Treatment algorithm of otogenic brain abscesses at our institution.
Treatment
| Publication | n | Treatment |
|---|---|---|
| Yang, 1981 | 263 | Repeated aspiration (44.2%), excision (32%), aspiration then excision (19%), drainage (2.5%) + antibiotics |
| Keet et al., 1990 | 233 | Burr hole aspiration (100%) + antibiotics |
| Bradley et al., 1984 | 139 | Aspiration (69%), late excision (8%), primary excision (6.4%), no surgical procedure (5%) + antibiotics |
| Pennybacker et al., 1961 | 85 | Burr hole aspiration + antibiotics |
| Newlands, 1965 | 80 | Burr hole aspiration + antibiotics |
| Fernandes et al., 1986 | 53 | Mastoidectomy; aspiration (100%) + antibiotics |
| Nunez and Browning, 1990 | 41 | Neurosurgery + antibiotics |
| Sennaroglu and Sozeri, 2000 | 41 | Mastoidectomy and abscess drainage (61%), burr hole aspiration (20%) craniotomy (15%) |
| Lavin et al., 2016 | 37 | Not specified |
| Prasad et al., 2006 | 37 | Burr hole aspiration + antibiotics |
| Dawes et al., 1960 | 30 | Burr hole aspiration + antibiotics |
| Kangsanarak et al., 1995 | 29 | Drainage, aspiration + antibiotics |
| Rupa and Raman,1991 | 27 | Surgical aspiration + antibiotics |
| Beller et al., 1973 | 27 | Drainage (7%), aspiration (40%), primary resection (32%), aspiration and resection (20%) + antibiotics |
| Sichiza et al., 2005 | 27 | Aspiration (87%), excision (13%) + antibiotics |
| Penido et al., 2005 | 26 | Surgical aspiration + antibiotics |
| Lakshmi et al., 1993 | 24 | Burr hole aspiration + antibiotics |
| Morgan et al., 1973 | 21 | For all brain abscesses: excision (31%), aspiration (66%) using thorostat + abx |
| Yen et al., 1995 | 19 | Neurosurgical management + antibiotics; radical mastoidectomy (63%) |
| Brand et al., 1984 | 15 | Neurosurgical management + antibiotics |